In hepatocellular carcinoma (HCC), its overexpression predicts early recurrence [14]; in breast cancer, it stabilizes ERα to accelerate disease progression [15]; and in bladder cancer, it activates NF‐κB signaling to promote tumor progression [16]. Here, NFKB1 is linked to breast carcinoma.